Abstract: SDRMs were identified in 14/219 (6.4%) subjects; 8/14 were resistant to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs; T69D, L74V, V75M, M184V/I and K219R), 5/14 to non-nucleoside reverse transcriptase inhibitors (NNRTIs; K103N, V106M, Y181C, Y188C and G190A), 1/14 to both NRTIs and NNRTIs (D67N and Y181C) and none to PMID: 22474222
2012
Clinical infectious diseases
Abstract: The most common DRMs were M184V (53.5%), K103N (28.9%), Y181C (15.5%), and G190A (14.1%).
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
PMID: 22492850
2012
The Journal of infectious diseases
Abstract: HIV-1 infected pregnant women administered sdNVP with or without short-course ZDV were assessed for HIV-1 mutations (K103N, Y181C, G190A, and V106M) prior to delivery and postpartum.
Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.
Introduction: There are four types of NNRTIs-resistant mutations: (1) Primary mutation: these mutations emerge earliest during therapy and cause high-level resistance to one or more NNRTIs, including K103N/S, Y181C/I/V, V106A/M, Y188L/C/H, and G190A/S/E.
Discussion: covered the virus containing K101E/Y181C/G190A and other mutations could increase 893-fold resistance to NVP.
Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase.
PMID: 22574920
2012
The journal of physical chemistry. B
Abstract: The dissociation constant is decreased for the Y188C and G190A (2-fold), the M184V (5-fold), and the Y188C/Y188C mutant (10-fold), due to stronger electrostatic interactions between LRV and RT.
Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia.
Abstract: With regard to NNRTI mutations, G190S/A was the most frequent mutation, which might be a preferred mutations for subtype A.
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.
PMID: 22592583
2012
Journal of acquired immune deficiency syndromes (1999)
4Method: ARV resistance was defined by mutations at the following positions: M41L, A62V, K65R, D67N, T69ins, K70R, L74VI, Y115F, F116Y, Q151M, M184VI, T210W, T215YF and K219QE for Nucleoside Reverse Transcriptase Inhibitors (NRTI), L100I, K101EP, K103NS, V106AM
K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
Discussion: Second, there is an antagonism between TAMs and K65R, while the latter can be found in association with NAMs (Q151M) and is considered to be increasingly selected in the presence of DRMs to NNRTIs and particularly Y181C and G190A.
Discussion: The Sanger results of isolates from treated patients were as expected with a predominance of M184V, numerous TAMs of pathway1 (M41L, D67N, K70R, L210W, T215Y/F) and DRMs to NNRTIs (mainly K101E, K103N, V106M
New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
PMID: 22712652
2012
Journal of medicinal chemistry
Abstract: In particular, compound 9 was uniformly effective against the mutant Y181C, Y188L, and K103N HIV-1 strains; it was highly active against the multidrug resistant mutant IRLL98 HIV-1 strain bearing the K101Q, Y181C, and G190A mutations conferring resistance to NVP, DLV, and EFV and several HIV-1 clades A in PBMC.
HIV mutation literature information.
PMID: 
2012
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT